Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2023

Genmab — Januar 2023

Planlagt Fastgjort Låst Flyttet Genmab
644 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #71

    Mandagens aviser med Novozymes, TDC og Novo Holdings https://www.proinvestor.com/investornyt/924542/mandagens-aviser-med-novozymes-tdc-og-novo-holdings

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #72

      Asien: Flotte plusser op til regnskabssæsonen - Tokyo lukket - NY https://www.proinvestor.com/investornyt/924550/asien-flotte-plusser-op-til-regnskabssaesonen-tokyo-lukket-ny

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #73

        Godmorgen 🙂

        1 Reply Last reply
        0
        • B Offline
          B Offline
          bibob
          wrote on sidst redigeret af
          #74

          God morgen. 🙂

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Stroka
            wrote on sidst redigeret af
            #75

            God morgen 🙂

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #76

              JNJ yesterday very positive on Genmab products again; biggest area of growth is MM portfolio; biggest disconnect wih the market is that these drugs do not cannibalise each other but create the treatment paradigm that is different by combining + sequencing these different medicines

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #77

                Mariposa/ Rybrevant ; runs through 2024, but potential interim analysis 2023; large market, very large opportunity for growth

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #78

                  This feedback, coupled with positive assessment of Briuvi from KOLs, suggests that TG Therapeutics has a competitive product in its hands, though it simultaneously places further emphasis on the key outstanding question of whether a company of its size and relative commercial experience can maximise this opportunity. KOLs have raised the same issue and speculated that Briuvi could become the subject of a co-marketing agreement or perhaps even trigger a larger company to acquire TG Therapeutics.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #79

                    Just a moment...

                    favicon

                    (firstwordpharma.com)

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #80

                      Nice comments EL

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #81

                        https://investor.seagen.com/events-and-presentations/default.aspx
                        Seagen JPM presentation

                        1 Reply Last reply
                        0
                        • StockBullS Offline
                          StockBullS Offline
                          StockBull
                          wrote on sidst redigeret af
                          #82

                          Good info EL

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Stroka
                            wrote on sidst redigeret af
                            #83

                            God morgen 🙂

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #84

                              Norsk finanshus sænker Genmab til "sælg" https://www.proinvestor.com/investornyt/925657/norsk-finanshus-saenker-genmab-til-saelg

                              1 Reply Last reply
                              0
                              • J Offline
                                J Offline
                                JKY_VH
                                wrote on sidst redigeret af
                                #85

                                Fred være med det og god morgen;-)

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bibob
                                  wrote on sidst redigeret af
                                  #86

                                  God morgen. 🙂

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #87

                                    DARA in refractory autoimmune conditions https://twitter.com/nikolasruffer/status/1612940755194073089

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #88

                                      https://investors.abbvie.com/static-files/4d7aae8a-65ca-45f9-bc0f-a169b5a7dc9d
                                      AbbVie JPM presentation

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Stockwatch1
                                        wrote on sidst redigeret af
                                        #89

                                        DNB: We expect focus in 2023 to be on epcoritamab’s approval,
                                        launch and initial uptake, but believe consensus is
                                        overestimating the latter while underestimating costs. In
                                        other words, in our view, we are not looking at a Darzalexlike launch curve. We see a risk of the 2023 guidance
                                        disappointing consensus

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Stockwatch1
                                          wrote on sidst redigeret af
                                          #90

                                          DNB: we have cut our target price
                                          DKK2,750 (2,982) and downgraded to SELL (HOLD)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper